Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02905591Phase 2Active Not Recruiting

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Role: lead

NCT03541486Phase 2Withdrawn

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients

Role: lead

NCT01752491Phase 1Completed

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Role: lead

NCT02420314Phase 2Completed

Pharmacological Ascorbate for Lung Cancer

Role: lead

All 4 trials loaded